4564.T OncoTherapy Science (JPX) pre-market: earnings Jan 30 could shift price
The 4564.T stock opened pre-market at ¥22.00, up 4.76%, as investors position ahead of OncoTherapy Science’s earnings on 30 Jan 2026. Volume is 25,430,900 versus a 50-day average of 53,676,932, showing subdued liquidity but increased interest. Upcoming clinical updates and cash runway will likely drive the report and short-term volatility on the JPX market in Japan.
4564.T stock: pre-market snapshot and earnings trigger
OncoTherapy Science, Inc. (4564.T) trades on the JPX in JPY. Price is ¥22.00 with a day low of ¥21.00 and day high of ¥22.00. The company set an earnings announcement for 2026-01-30. Today’s move reflects positioning ahead of quarterly results and clinical-readout guidance.
Earnings preview and what to watch in the 4564.T earnings report
Key items for the 4564.T earnings release: management commentary on the Phase III vaccine S-588410, updates on OTS167 and OTS964 trials, and guidance on contract analysis revenues. Expect remarks on cash burn, R&D spend and any revised timelines. A clear update on patient enrollment or regulatory milestones would be an immediate price catalyst.
Financials and valuation metrics for 4564.T stock
OncoTherapy shows weak profitability but strong liquidity. Reported EPS -2.83 and negative PE (-7.77). Price-to-book is 4.06 and price-to-sales is 7.54. The company holds ¥5.26 cash per share and a current ratio of 8.63, indicating a healthy short-term balance sheet despite operating losses. One metric per claim: high R&D intensity at 53.91% of revenue supports pipeline development but pressures margins.
Pipeline catalysts and sector context for 4564.T opportunities
OncoTherapy’s pipeline includes Phase III S-588410 (esophageal cancer) and several early-stage assets like OTS167 and OTSA101. Clinical progress is the primary upside driver. Compared with the Healthcare sector average PE of 23.48, OncoTherapy’s negative earnings and biotech staging justify a speculative valuation. Sector momentum in Japan is modest; healthcare YTD performance is +3.28%, which may limit broad-sector spillover.
Technicals, liquidity and trading flow for 4564.T analysis
Technically, RSI 68.81 and CCI 277.90 show near-overbought conditions in the short term. MACD histogram is positive (0.40). Average volume is 53,676,932; today’s 25,430,900 indicates lighter trade than usual. Bollinger upper band sits at ¥23.10. Short-term traders should watch ATR ¥1.54 for expected intraday swings.
Meyka AI rates 4564.T with a score out of 100 and price forecast
Meyka AI rates 4564.T with a score out of 100: 65.52 / 100 (Grade B — HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of ¥28.51 and a yearly price of ¥18.22. Compared with the current ¥22.00, the monthly model implies +29.59% upside and the yearly model implies -17.18% downside. Forecasts are model-based projections and not guarantees.
Final Thoughts
OncoTherapy Science (4564.T) is a speculative biotech play on the JPX ahead of an earnings report on 2026-01-30. The stock sits at ¥22.00 with negative EPS (-2.83) and a PB of 4.06, reflecting market expectations tied to clinical outcomes rather than near-term profits. The immediate outlook centers on trial updates for S-588410 and management guidance on R&D pacing and cash runway. Technicals show short-term strength but limited liquidity, which can exaggerate moves. Meyka AI’s models present a mixed view: a monthly target of ¥28.51 (implying ~+29.6% upside) versus a yearly target of ¥18.22 (implying ~-17.2%). Use the earnings report as a decision point: positive clinical or enrollment news could validate upside scenarios, while muted guidance would likely pressure the stock. Meyka AI, an AI-powered market analysis platform, flags 4564.T as a HOLD under current information and advises investors to weigh pipeline binary risk, balance-sheet strength, and sector comparables in JPY before allocating capital.
FAQs
When does OncoTherapy (4564.T) report earnings?
OncoTherapy (4564.T) will announce results on 2026-01-30. The report should cover clinical updates, R&D spend and cash position, key items that typically move the stock in the JPX pre-market session.
What are the main valuation metrics for 4564.T stock?
Key metrics: EPS -2.83, PE -7.77 (negative), PB 4.06, cash per share ¥5.26, and a strong current ratio 8.63. These figures show liquidity strength and earnings weakness.
How does Meyka AI view 4564.T stock ahead of earnings?
Meyka AI rates 4564.T 65.52/100 (B, HOLD). The model highlights clinical catalysts and a mixed forecast: monthly ¥28.51 and yearly ¥18.22. Forecasts are projections and not guarantees.
What technical signals should traders watch for 4564.T?
Watch RSI 68.81 and CCI 277.90 for short-term overbought risk, MACD histogram 0.40 for momentum, and ATR ¥1.54 for expected daily range. Volume below average can amplify moves.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
